Hetlioz®, Hetlioz LQ™ (tasimelteon) – New orphan indication, new formulation approval
December 1, 2020 - Vanda Pharmaceuticals announced the FDA approval of Hetlioz (tasimelteon) capsules, for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older, and Hetlioz LQ oral suspension for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 to 15 years of age.
Top